Polaris Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Polaris Group sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Polaris Group: 13 sponsored US clinical trials, 1 recruiting.
Polaris Group sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 9 completed. 2 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Pancreatic Cancer, with 1 trials.
Top-decile sponsor footprint
Polaris Group ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
13 total, page 1 of 1
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
NCT05712694
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
NCT05001828
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
NCT02709512
PH 2 ADI-PEG 20 Acute Myeloid Leukemia
NCT01910012
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
NCT02101580
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
NCT02101593
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
NCT02102022
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
NCT02029690
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
NCT01948843
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
NCT01665183
Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient
NCT01528384
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
NCT01497925
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
NCT01287585
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Polaris Group pipeline
1 recruiting of 13 indexed (8% open); 9 completed (69%).
Phase mix: 2 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Advanced Pancreatic Cancer (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Polaris Group: open-pipeline peers nationwide
Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Polaris Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
- Fresenius Medical Care North America · 8% recruiting · 13 trials
Related
What to do with this Polaris Group page
13 registered trials is a research-attention snapshot, not an endorsement of Polaris Group or any single study.
- 1 of Polaris Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Pancreatic Cancer is the condition Polaris Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Pancreatic Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Polaris Group pipeline card: 13 registered trials from official public datasets.Report a data error.